TJX
62
-2
THC
60
-5
HSIC
45
5
SO
57
6
NEM
40
3
VZ
44
4
DD
53
-6
IPG
34
-9
AMAT
33
-13
CMG
66
-4
MAS
52
-4
CL
54
3
PLD
45
-5
KLAC
38
-6
KMI
69
-2
HCP
56
-8
CA
22
-3
V
64
-2
KIM
72
2
DHI
44
-3
TJX
62
-2
THC
60
-5
HSIC
45
5
SO
57
6
NEM
40
3
VZ
44
4
DD
53
-6
IPG
34
-9
AMAT
33
-13
CMG
66
-4
MAS
52
-4
CL
54
3
PLD
45
-5
KLAC
38
-6
KMI
69
-2
HCP
56
-8
CA
22
-3
V
64
-2
KIM
72
2
DHI
44
-3
Financhill
Back

Matthews Emerging Markets Ex Chn Act ETF Vs. Halozyme Therapeutics Industry Stock Comparison

Sell
32

MEMX
Matthews Emerging Markets Ex Chn Act ETF

Last Price:
29.22
Seasonality Move:
8.21%
Sell
39

HALO
Halozyme Therapeutics

Last Price:
45.65
Seasonality Move:
17.03%
Sell
32
Matthews Emerging Markets Ex Chn Act ETF (MEMX) is a Sell

Is Matthews Emerging Markets Ex Chn Act ETF a Buy, Sell or Hold?

  • The current Matthews Emerging Markets Ex Chn Act ETF [MEMX] share price is $29.27. The Score for MEMX is 32, which is 36% below its historic median score of 50, and infers higher risk than normal.
  • MEMX is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
39
Halozyme Therapeutics (HALO) is a Sell

Is Halozyme Therapeutics a Buy, Sell or Hold?

  • The current Halozyme Therapeutics [HALO] share price is $45.65. The Score for HALO is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.
  • HALO is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.

MEMX Stock Price Chart

What is Matthews Emerging Markets Ex Chn Act ETF's stock price today?

  • The Matthews Emerging Markets Ex Chn Act ETF share price today is $29.27
    Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and MEMX is experiencing slight buying pressure.

HALO Stock Price Chart

What is Halozyme Therapeutics's stock price today?

  • The Halozyme Therapeutics share price today is $45.65
    Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and HALO is experiencing selling pressure, which indicates risk of future bearish movement.

MEMX Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): -0.29 Sell
Relative Strength Index (14 RSI): 28.6 Sell
Chaikin Money Flow: 2391 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (29.87 - 30.77) Sell
Bollinger Bands (100): (29.76 - 30.98) Sell

HALO Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): -0.02 Sell
Relative Strength Index (14 RSI): 30.2 Sell
Chaikin Money Flow: -7140517 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (49.94 - 58.56) Sell
Bollinger Bands (100): (52.16 - 60.38) Sell

MEMX Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 29.85 Sell
20-day SMA: 30.22 Sell
50-day SMA: 30.5 Sell
200-day SMA: 29.64 Sell
8-day EMA: 29.73 Sell
20-day EMA: 30.08 Sell
50-day EMA: 30.3 Sell
200-day EMA: 29.51 Sell

HALO Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 57.53 Sell
20-day SMA: 54.48 Sell
50-day SMA: 56.18 Sell
200-day SMA: 48.93 Sell
8-day EMA: 55 Sell
20-day EMA: 55.41 Sell
50-day EMA: 55.64 Sell
200-day EMA: 50.73 Sell

Matthews Emerging Markets Ex Chn Act ETF Earnings Growth & MEMX Earnings Dates

  • Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.

Halozyme Therapeutics Earnings Growth & HALO Earnings Dates

  • Analysts estimate an earnings increase this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.30 per share, and an increase next year of $0.71 per share.

Matthews Emerging Markets Ex Chn Act ETF Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):

Halozyme Therapeutics Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):